Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Oncology

External Link

Lung cancer

Articles 1 - 13 of 13

Full-Text Articles in Medicine and Health Sciences

Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach, Edward Yu, Craig Lewis, Ana Trejos, Rajni Patel, Richard Malthaner Jul 2015

Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach, Edward Yu, Craig Lewis, Ana Trejos, Rajni Patel, Richard Malthaner

Richard A. Malthaner

New technological concepts have been evolving to manage the relative poor prognosis of lung cancer. Brachytherapy is becoming an option for both unresectable and early resectable lung cancer. Three-dimensional ultrasound (US) of lung tumours and image-guided minimally invasive robotics-assisted brachytherapy are feasible for dosimetry planning and management of lung tumours. The present article reviews the current knowledge of lung brachytherapy and discusses its potential in future management of lung cancer.


Definitive Radiation Therapy Management For Medically Non-Resectable Clinically Localised Non-Small Cell Lung Cancer: Results & Prognostic Factors, Edward Yu, Patricia Tai, Robert Ash, Michael Lee, Larry Stitt, George Rodrigues, Rashid Dar, Mark Vincent, Richard Inculet, Richard Malthaner Jul 2015

Definitive Radiation Therapy Management For Medically Non-Resectable Clinically Localised Non-Small Cell Lung Cancer: Results & Prognostic Factors, Edward Yu, Patricia Tai, Robert Ash, Michael Lee, Larry Stitt, George Rodrigues, Rashid Dar, Mark Vincent, Richard Inculet, Richard Malthaner

Richard A. Malthaner

The aim of this paper is to review the experience of radical radiation therapy and the prognostic factors of patient outcome for clinically localised, medically inoperable non-small cell lung cancer (NSCLC) patients. Clinically staged node-negative NSCLC patients who were not a surgical candidates due to co-morbid diseases but who were eligible for curative treatment, were reviewed in the London Regional Cancer Program (LRCP). This study population was treated between 1st Jan 1985 to 31st Jan 2004. Patients were excluded if they were previously treated with chest radiotherapy. Patients with localised disease, but who refused surgery, were also included in the …


Mira V: An Integrated System For Minimally Invasive Robot-Assisted Lung Brachytherapy, A. Trejos, A. Lin, S. Mohan, H. Bassan, C. Edirisinghe, R. Patel, C. Lewis, E. Yu, A. Fenster, R. Malthaner Jul 2015

Mira V: An Integrated System For Minimally Invasive Robot-Assisted Lung Brachytherapy, A. Trejos, A. Lin, S. Mohan, H. Bassan, C. Edirisinghe, R. Patel, C. Lewis, E. Yu, A. Fenster, R. Malthaner

Richard A. Malthaner

An integrated system for minimally invasive robot-assisted image-guided lung brachytherapy has been developed. The system incorporates an experimental setup for accurate radioactive seed placement with commercially available dosimetry planning software. The end result is a complete system that allows planning and executing a brachytherapy procedure with increased accuracy. The results of the in vitro seed placement evaluation show that seed misplacement has a significant effect on the volume receiving more than 200% of the dose (V200), and the minimum dosage received by 90% of the volume (D90).


The 4th Annual Ontario Thoracic Cancer Conference At Niagara-On-The-Lake, Y. Ung, E. Yu, R. Malthaner, R. Burkes, P. Ellis, G. Goss, H. Solow, S. Irvine, S. Laffan Jul 2015

The 4th Annual Ontario Thoracic Cancer Conference At Niagara-On-The-Lake, Y. Ung, E. Yu, R. Malthaner, R. Burkes, P. Ellis, G. Goss, H. Solow, S. Irvine, S. Laffan

Richard A. Malthaner

The 4th annual Ontario Thoracic Cancer Conference at Niagara-on-the-lake focused on the themes of innova- tions in the management of lung cancer, controversies in the management of esophageal cancer, and molecu- lar targeted therapies in lung cancer. This conference summary highlights the presentations and provides clinicians with a referenced update on these topics.


Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach, Edward Yu, Craig Lewis, Ana Trejos, Rajni Patel, Richard Malthaner Jul 2015

Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach, Edward Yu, Craig Lewis, Ana Trejos, Rajni Patel, Richard Malthaner

Richard A. Malthaner

New technological concepts have been evolving to manage the relative poor prognosis of lung cancer. Brachytherapy is becoming an option for both unresectable and early resectable lung cancer. Three-dimensional ultrasound (US) of lung tumours and image-guided minimally invasive robotics-assisted brachytherapy are feasible for dosimetry planning and management of lung tumours. The present article reviews the current knowledge of lung brachytherapy and discusses its potential in future management of lung cancer.


Definitive Radiation Therapy Management For Medically Non-Resectable Clinically Localised Non-Small Cell Lung Cancer: Results & Prognostic Factors, Edward Yu, Patricia Tai, Robert Ash, Michael Lee, Larry Stitt, George Rodrigues, Rashid Dar, Mark Vincent, Richard Inculet, Richard Malthaner Jul 2015

Definitive Radiation Therapy Management For Medically Non-Resectable Clinically Localised Non-Small Cell Lung Cancer: Results & Prognostic Factors, Edward Yu, Patricia Tai, Robert Ash, Michael Lee, Larry Stitt, George Rodrigues, Rashid Dar, Mark Vincent, Richard Inculet, Richard Malthaner

Richard A. Malthaner

The aim of this paper is to review the experience of radical radiation therapy and the prognostic factors of patient outcome for clinically localised, medically inoperable non-small cell lung cancer (NSCLC) patients. Clinically staged node-negative NSCLC patients who were not a surgical candidates due to co-morbid diseases but who were eligible for curative treatment, were reviewed in the London Regional Cancer Program (LRCP). This study population was treated between 1st Jan 1985 to 31st Jan 2004. Patients were excluded if they were previously treated with chest radiotherapy. Patients with localised disease, but who refused surgery, were also included in the …


Mira V: An Integrated System For Minimally Invasive Robot-Assisted Lung Brachytherapy, A. Trejos, A. Lin, S. Mohan, H. Bassan, C. Edirisinghe, R. Patel, C. Lewis, E. Yu, A. Fenster, R. Malthaner Jul 2015

Mira V: An Integrated System For Minimally Invasive Robot-Assisted Lung Brachytherapy, A. Trejos, A. Lin, S. Mohan, H. Bassan, C. Edirisinghe, R. Patel, C. Lewis, E. Yu, A. Fenster, R. Malthaner

Richard A. Malthaner

An integrated system for minimally invasive robot-assisted image-guided lung brachytherapy has been developed. The system incorporates an experimental setup for accurate radioactive seed placement with commercially available dosimetry planning software. The end result is a complete system that allows planning and executing a brachytherapy procedure with increased accuracy. The results of the in vitro seed placement evaluation show that seed misplacement has a significant effect on the volume receiving more than 200% of the dose (V200), and the minimum dosage received by 90% of the volume (D90).


The 4th Annual Ontario Thoracic Cancer Conference At Niagara-On-The-Lake, Y. Ung, E. Yu, R. Malthaner, R. Burkes, P. Ellis, G. Goss, H. Solow, S. Irvine, S. Laffan Jul 2015

The 4th Annual Ontario Thoracic Cancer Conference At Niagara-On-The-Lake, Y. Ung, E. Yu, R. Malthaner, R. Burkes, P. Ellis, G. Goss, H. Solow, S. Irvine, S. Laffan

Richard A. Malthaner

The 4th annual Ontario Thoracic Cancer Conference at Niagara-on-the-lake focused on the themes of innova- tions in the management of lung cancer, controversies in the management of esophageal cancer, and molecu- lar targeted therapies in lung cancer. This conference summary highlights the presentations and provides clinicians with a referenced update on these topics.


Prophylactic Cranial Irradiation For Patients With Limited-Stage Small-Cell Lung Cancer With Response To Chemoradiation, Patricia Tai, Avi Assouline, Kurian Joseph, Larry Stitt, Edward Yu Dec 2012

Prophylactic Cranial Irradiation For Patients With Limited-Stage Small-Cell Lung Cancer With Response To Chemoradiation, Patricia Tai, Avi Assouline, Kurian Joseph, Larry Stitt, Edward Yu

Edward Yu

Background Previous clinical studies have generally reported that prophylactic cranial irradiation (PCI) was given to patients with a complete response (CR) to chemotherapy and chest radiotherapy in limited-stage small-cell lung cancer (SCLC). It is not clear if those with incomplete response (IR) would benefit from PCI. Patients and Methods The Saskatchewan experience from 1981 through 2007 was reviewed. Patients were treated with chest radiotherapy and chemotherapy with or without PCI (typical doses: 2500 cGy in 10 fractions over 2 weeks, 3000 cGy in 15 fractions over 3 weeks, or 3000 cGy in 10 fractions over 2 weeks). Results There were …


Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach, Edward Yu, Craig Lewis, Ana Trejos, Rajni Patel, Richard Malthaner Sep 2011

Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach, Edward Yu, Craig Lewis, Ana Trejos, Rajni Patel, Richard Malthaner

Edward Yu

New technological concepts have been evolving to manage the relative poor prognosis of lung cancer. Brachytherapy is becoming an option for both unresectable and early resectable lung cancer. Three-dimensional ultrasound (US) of lung tumours and image-guided minimally invasive robotics-assisted brachytherapy are feasible for dosimetry planning and management of lung tumours. The present article reviews the current knowledge of lung brachytherapy and discusses its potential in future management of lung cancer.


The 4th Annual Ontario Thoracic Cancer Conference At Niagara-On-The-Lake, Y. Ung, E. Yu, R. Malthaner, R. Burkes, P. Ellis, G. Goss, H. Solow, S. Irvine, S. Laffan Dec 2008

The 4th Annual Ontario Thoracic Cancer Conference At Niagara-On-The-Lake, Y. Ung, E. Yu, R. Malthaner, R. Burkes, P. Ellis, G. Goss, H. Solow, S. Irvine, S. Laffan

Edward Yu

The 4th annual Ontario Thoracic Cancer Conference at Niagara-on-the-lake focused on the themes of innova- tions in the management of lung cancer, controversies in the management of esophageal cancer, and molecu- lar targeted therapies in lung cancer. This conference summary highlights the presentations and provides clinicians with a referenced update on these topics.


Mira V: An Integrated System For Minimally Invasive Robot-Assisted Lung Brachytherapy, A. Trejos, A. Lin, S. Mohan, H. Bassan, C. Edirisinghe, R. Patel, C. Lewis, E. Yu, A. Fenster, R. Malthaner Apr 2008

Mira V: An Integrated System For Minimally Invasive Robot-Assisted Lung Brachytherapy, A. Trejos, A. Lin, S. Mohan, H. Bassan, C. Edirisinghe, R. Patel, C. Lewis, E. Yu, A. Fenster, R. Malthaner

Edward Yu

An integrated system for minimally invasive robot-assisted image-guided lung brachytherapy has been developed. The system incorporates an experimental setup for accurate radioactive seed placement with commercially available dosimetry planning software. The end result is a complete system that allows planning and executing a brachytherapy procedure with increased accuracy. The results of the in vitro seed placement evaluation show that seed misplacement has a significant effect on the volume receiving more than 200% of the dose (V200), and the minimum dosage received by 90% of the volume (D90).


The Role Of Radiation Therapy On Medically Inoperable Clinically Localized Non-Small Cell Lung Patients: London Regional Cancer Program (Lrcp) Clinical Experience, Michael Lee, Edward Yu, Robert Ash, Patricia Tai, Larry Stitt, George Rodrigues, Rashid Dar, Mark Vincent, Richard Inculet, Richard Malthaner Dec 2005

The Role Of Radiation Therapy On Medically Inoperable Clinically Localized Non-Small Cell Lung Patients: London Regional Cancer Program (Lrcp) Clinical Experience, Michael Lee, Edward Yu, Robert Ash, Patricia Tai, Larry Stitt, George Rodrigues, Rashid Dar, Mark Vincent, Richard Inculet, Richard Malthaner

Edward Yu

Lung cancer is the most frequent cause of cancer death in both men and women in North America. In 2006, an estimated 22,700 Canadians will be diagnosed with lung cancer and 19,300 will die of it (Canadian Cancer Statistics 2006). Approximately 15-20% of NSCLC patients present with early or localized disease. Surgical resection of T1-2N0 NSCLC remains the treatment of choice for this population, and results in a 5-year survival rate of 50-70%. Patients deemed medically inoperable have been treated with non-surgical therapies, such as radiation therapy(RT), while some patients have simply been observed without any tumor therapy because of …